Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 5/2022

29-03-2022 | Obesity | Review

Primary Bariatric Procedures

Authors: Pichamol Jirapinyo, Christopher C. Thompson

Published in: Digestive Diseases and Sciences | Issue 5/2022

Login to get access

Abstract

Obesity is pandemic. It is estimated that by 2030, half of the U.S. population will have obesity. Current treatment options for obesity includes lifestyle modification, pharmacotherapy, endoscopic bariatric and metabolic therapy (EBMT) and bariatric surgery. Over the past decades, an increasing number of EBMTs have been developed and become available. As a gastroenterologist, it is therefore important to become familiar with the available EBMTs as well as their safety and efficacy profiles in order to educate and expeditiously refer patients for the appropriate therapy when eligible. This chapter will review currently available and upcoming EBMTs. Details on how the procedures are performed, their mechanisms of action as well as data from pivotal studies will be summarized.
Literature
1.
2.
Hales CM, Carroll MD, Fryar CD, et al. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief 2020(360);1–8.
3.
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med 2019;381:2440–2450.PubMedCrossRef
4.
Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ 2012;31:219–230.PubMedCrossRef
5.
6.
Muniraj T, Day LW, Teigen LM, et al. AGA clinical practice guidelines on intragastric balloons in the management of obesity. Gastroenterology 2021;160:1799–1808.PubMedCrossRef
7.
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 2014;129:S102–138.PubMedCrossRef
8.
Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obes Silver Spring Md 2014;22:5–13.CrossRef
9.
Sjöström L, Lindroos A-K, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683–2693.PubMedCrossRef
10.
11.
Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 2017;152:1791–1801.PubMedCrossRef
12.
Jirapinyo P, Thompson CC. Endoscopic bariatric and metabolic therapies: surgical analogues and mechanisms of action. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2017;15:619–630.
13.
ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy, Ginsberg GG, Chand B, et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc 2011;74:943–953.CrossRef
14.
ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy. A pathway to endoscopic bariatric therapies. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2011;7:672–682.
15.
Nieben OG, Harboe H. Intragastric balloon as an artificial bezoar for treatment of obesity. Lancet Lond Engl 1982;1:198–199.CrossRef
16.
Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc 1989;35:381–385.PubMedCrossRef
17.
Shah R, Davitkov P, Abu Dayyeh BK, et al. AGA technical review on intragastric balloons in the management of obesity. Gastroenterology 2021;160:1811–1830.PubMedCrossRef
18.
Mion F, Napoléon B, Roman S, et al. Effects of intragastric balloon on gastric emptying and plasma ghrelin levels in non-morbid obese patients. Obes Surg 2005;15:510–516.PubMedCrossRef
19.
Dayyeh BKA, Woodman G, Acosta A, et al. 380 baseline gastric emptying and its change in response to diverse endoscopic bariatric therapies predict weight change after intervention. Gastroenterology 2016;150:S86.CrossRef
20.
Dayyeh BKA, Eaton LL, Woodman G, et al. 444 A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subjects. Gastrointest Endosc 2015;81:AB147.CrossRef
21.
Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes 2005 2017;41:427–433.
22.
Vargas EJ, Pesta CM, Bali A, et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2018;16:1073–1080.e1.
23.
ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015;82:425–438.e5.CrossRef
24.
Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating safety and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2013;9:290–295.CrossRef
25.
Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2015;11:874–881.CrossRef
26.
Agnihotri A, Xie A, Bartalos C, et al. Real-world safety and efficacy of fluid-filled dual intragastric balloon for weight loss. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2018;16:1081–1088.e1.
27.
Mion F, Ibrahim M, Marjoux S, et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg 2013;23:730–733.PubMedCrossRef
28.
Sullivan S, Swain JM, Woodman G, et al. 812d The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. Gastroenterology 2016;150:S1267.CrossRef
29.
Moore RL, Seger MV, Garber SM, et al. Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of U.S. commercialization. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2019;15:417–423.CrossRef
30.
Machytka E, Klvana P, Kornbluth A, et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 2011;21:1499–1507.PubMedPubMedCentralCrossRef
31.
Dayyeh BKA, Noar MD, Lavin T, et al. 176 Pivotal randomized-controlled trial of the adjustable (SPATZ-3) intragastric balloon system for weight loss. Gastrointest Endosc 2019;89:AB58–AB59.CrossRef
32.
Ienca R, Al Jarallah M, Caballero A, et al. The procedureless elipse gastric balloon program: multicenter experience in 1770 consecutive patients. Obes Surg 2020;30:3354–3362.PubMedPubMedCentralCrossRef
33.
Ramai D, Singh J, Mohan BP, et al. Influence of the elipse intragastric balloon on obesity and metabolic profile: a systematic review and meta-analysis. J Clin Gastroenterol 2021;55(10):36–841.CrossRef
34.
Thompson CC, Slattery J, Bundga ME, et al. Peroral endoscopic reduction of dilated gastrojejunal anastomosis after Roux-en-Y gastric bypass: a possible new option for patients with weight regain. Surg Endosc 2006;20:1744–1748.PubMedCrossRef
35.
Fogel R, De Fogel J, Bonilla Y, et al. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients. Gastrointest Endosc 2008;68:51–58.PubMedCrossRef
36.
Devière J, Ojeda Valdes G, Cuevas Herrera L, et al. Safety, feasibility and weight loss after transoral gastroplasty: first human multicenter study. Surg Endosc 2008;22:589–598.PubMedCrossRef
37.
Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc 2011;74:1248–1258.PubMedCrossRef
38.
Brethauer SA, Chand B, Schauer PR, et al. Transoral gastric volume reduction for weight management: technique and feasibility in 18 patients. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2010;6:689–694.CrossRef
39.
Brethauer SA, Chand B, Schauer PR, et al. Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2012;8:296–303.CrossRef
40.
Kumar N, Sahdala HNP, Shaikh S, et al. Mo1155 Endoscopic sleeve gastroplasty for primary therapy of obesity: initial human cases. Gastroenterology 2014;146:S-571-S-572.CrossRef
41.
Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a potential endoscopic alternative to surgical sleeve gastrectomy for treatment of obesity. Gastrointest Endosc 2013;78:530–535.PubMedCrossRef
42.
Sharaiha RZ, Kedia P, Kumta N, et al. Initial experience with endoscopic sleeve gastroplasty: technical success and reproducibility in the bariatric population. Endoscopy 2015;47:164–166.PubMed
43.
Lopez-Nava G, Sharaiha RZ, Vargas EJ, et al. Endoscopic sleeve gastroplasty for obesity: a multicenter study of 248 patients with 24 months follow-up. Obes Surg 2017;27:2649–2655.PubMedCrossRef
44.
Alqahtani A, Al-Darwish A, Mahmoud AE, et al. Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients. Gastrointest Endosc 2019;89:1132–1138.PubMedCrossRef
45.
Sharaiha RZ, Hajifathalian K, Kumar R, et al. Five-year outcomes of endoscopic sleeve gastroplasty for the treatment of obesity. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2020;19:1051–1057.
46.
Barrichello S, Hourneaux de Moura DT, Hourneaux de Moura EG, et al. Endoscopic sleeve gastroplasty in the management of overweight and obesity: an international multicenter study. Gastrointest Endosc 2019;90:770–780.PubMedCrossRef
47.
Hedjoudje A, Dayyeh BA, Cheskin LJ, et al. Efficacy and safety of endoscopic sleeve gastroplasty: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2019;18:1043–1053.
48.
Abu Dayyeh BK, Acosta A, Camilleri M, et al. Endoscopic sleeve gastroplasty alters gastric physiology and induces loss of body weight in obese individuals. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc 2017;15:37–43.e1.
49.
Sullivan S, Swain JM, Woodman G, et al. 100 12 Month randomized Sham controlled trial evaluating the safety and efficacy of targeted use of endoscopic suture anchors for primary obesity: the ESSENTIAL study. Gastroenterology 2016;150:S25–S26.CrossRef
50.
Espinós JC, Turró R, Mata A, et al. Early experience with the Incisionless Operating Platform™ (IOP) for the treatment of obesity: the Primary Obesity Surgery Endolumenal (POSE) procedure. Obes Surg 2013;23:1375–1383.PubMedCrossRef
51.
Miller K, Turró R, Greve JW, et al. MILEPOST multicenter randomized controlled trial: 12-month weight loss and satiety outcomes after pose SM versus medical therapy. Obes Surg 2017;27:310–322.PubMedCrossRef
52.
Singh S, Bazarbashi AN, Khan A, et al. Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis. Surg Endosc. 2021;36:252–266.PubMedCrossRef
53.
Jirapinyo P, Thompson CC. Gastric plications for weight loss: distal primary obesity surgery endoluminal through a belt-and-suspenders approach. VideoGIE Off Video J Am Soc Gastrointest Endosc 2018;3:296–300.
54.
Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: technical success and safety of a novel technique (with video). Gastrointest Endosc 2020;91:1388–1394.PubMedPubMedCentralCrossRef
55.
Lopez Nava G, Asokkumar R, Laster J, et al. Primary obesity surgery endoluminal (POSE-2) procedure for treatment of obesity in clinical practice. Endoscopy 2020;53:1169–1173.PubMed
56.
Espinós JC, Turró R, Moragas G, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE procedure. Obes Surg 2016;26:1081–1089.PubMedCrossRef
57.
Lopez-Nava G, Asokkumar R, Rull A, et al. Safety and feasibility of a novel endoscopic suturing device (EndoZip TM) for treatment of obesity: first-in-human study. Obes Surg 2020;30:1696–1703.PubMedCrossRef
58.
Huberty V, Machytka E, Boškoski I, et al. Endoscopic gastric reduction with an endoluminal suturing device: a multicenter prospective trial with 1-year follow-up. Endoscopy 2018;50:1156–1162.PubMedCrossRef
59.
Huberty V, Boskoski I, Bove V, et al. Endoscopic sutured gastroplasty in addition to lifestyle modification: short-term efficacy in a controlled randomised trial. Gut 2020;70:1479–1485.CrossRef
60.
61.
62.
Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013;145:1245–1252.e1–5.PubMedCrossRef
63.
Thompson CC, Dayyeh BKA, Kushner R, et al. 381 The AspireAssist is an effective tool in the treatment of class II and class III obesity: results of a 1-year clinical trial. Gastroenterology 2016;150:S86.CrossRef
64.
Thompson CC, Abu Dayyeh BK, Kushnir V, et al. Aspiration therapy for the treatment of obesity: 4-year results of a multicenter randomized controlled trial. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2019;15:1348–1354.CrossRef
65.
Jirapinyo P, Kumar N, Saumoy M, et al. Association for Bariatric Endoscopy systematic review and meta-analysis assessing the American Society for Gastrointestinal Endoscopy Preservation and Incorporation of Valuable Endoscopic Innovations thresholds for aspiration therapy. Gastrointest Endosc 2021;93:334–342.e1.PubMedCrossRef
66.
McIntosh CHS, Widenmaier S, Kim S-J. Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP). Vitam Horm 2009;80:409–471.PubMedCrossRef
67.
Punjabi M, Arnold M, Geary N, et al. Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiol Behav 2011;105:71–76.PubMedCrossRef
68.
Meek CL, Lewis HB, Reimann F, et al. The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones. Peptides 2016;77:28–37.PubMedCrossRef
69.
Rodriguez-Grunert L, Galvao Neto MP, Alamo M, et al. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 2008;4:55–59.CrossRef
70.
Rohde U, Hedbäck N, Gluud LL, et al. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2016;18:300–305.PubMedCrossRef
71.
Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care 2018;41:1106–1115.PubMedCrossRef
72.
Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care 2016;39(12):2254–2261.PubMedCrossRef
73.
van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: 1 year results from the first international, open-label, prospective, multicentre study. Gut 2019;69:295–303.PubMedCrossRef
74.
de Oliveira GHP, de Moura DTH, Funari MP, et al. Metabolic effects of endoscopic duodenal mucosal resurfacing: a systematic review and meta-analysis. Obes Surg 2021;31:1304–1312.PubMedCrossRef
75.
Machytka E, Bužga M, Zonca P, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in patients with obesity and diabetes. Gastrointest Endosc 2017;86:904–912.PubMedCrossRef
76.
Sauer N, Rösch T, Pezold J, et al. A new endoscopically implantable device (SatiSphere) for treatment of obesity–efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg 2013;23:1727–1733.PubMedCrossRef
77.
Cooper Z, Cooper PJ, Fairburn CG. The validity of the eating disorder examination and its subscales. Br J Psychiatry J Ment Sci 1989;154:807–812.CrossRef
78.
79.
80.
Jirapinyo P, Thompson CC. How to incorporate bariatric training into your fellowship program. Gastroenterology 2019;157:9–13.PubMedCrossRef
Metadata
Title
Primary Bariatric Procedures
Authors
Pichamol Jirapinyo
Christopher C. Thompson
Publication date
29-03-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-022-07393-z

Other articles of this Issue 5/2022

Digestive Diseases and Sciences 5/2022 Go to the issue

Original Article

Stress Hyperglycemia Is Independently Associated with Persistent Organ Failure in Acute Pancreatitis

Review

Endoscopic Management of Pancreatobiliary Malignancies

Original Article

Carbonic Anhydrases II, IX, and XII in Reflux Esophagitis

Review

POEM, GPOEM, and ZPOEM

Correction

Correction to: Cost‑Effectiveness of Empirical Bismuth‑Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication

Review

Advanced Imaging of the Biliary System and Pancreas
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits